15 Apr, 2022 Could the Specter of March-In Rights Finally Impact Drug Pricing Reform? By Kristen Riemenschneider Joshua Samuel On March 24, 2022 a group of public interest organizations filed a petition urging the Department of Health and Human Services (“HHS”) to...
24 Jan, 2022 Is it time for big biopharma companies to rethink the use of federal funding for R&D? By Kristen Riemenschneider This article was originally published in STAT on January 18, 2022. I have been negotiating with representatives of the federal government...
30 Aug, 2021 Trying cases during trying times: Recommendations for the bench and bar By Eric Bruce Jennifer Loeb With the recent and unfortunate surge of the delta variant, it’s clear that judges and lawyers will need to adapt to new ways of trying...
16 Mar, 2021 Digital Bank Robbers: Sanctions Risks for Digital Currency Service Companies By Nabeel Yousef Stephanie Brown Cripps Amy Cattle Andrew Bulovsky +1 more... Show less On February 17, 2021, the US Department of Justice (DOJ) unsealed charges against three North Koreans accused of conspiring to steal and...
30 Jan, 2021 Risk Factor Disclosures for the Recovery Era By Valerie Ford Jacob Doru Gavril Sarah Solum Drew Liming +1 more... Show less You Mastered the COVID-19 Risk Disclosures; But Are You Ready for the Recovery? It’s early 2021. With a new year comes a new Form 10-K. ...
12 Oct, 2020 Can the Failing Firm Defense Save a Deal in the Covid Era? By Julie Elmer Meredith Mommers Covid-19 has had a staggering impact on the U.S. economy in just eight months. Businesses large and small are struggling to stay afloat,...
01 Sep, 2020 Experiencing distress: M&A opportunities and challenges in the COVID era By Paul Humphreys Scott Talmadge Following the global implementation of stay-at-home orders in response to the novel coronavirus, businesses suffered unprecedented...
10 Jun, 2020 Three avenues for US distressed M&A By Mark Liscio Madlyn Primoff Scott Talmadge Compared to the 2007-08 financial crisis, the COVID-19 crisis is likely to produce a broader array of asset classes that become available...
06 Jun, 2020 Beyond the pandemic: the future of M&A By Matthew Herman After a period of hibernation, there are now signs of life returning to the M&A markets. In just the past week, we have seen a trio of...
01 Jun, 2020 The heightened need for boards to stay vigilant and keep stockholders informed as deal teams march to closing By Paul Tiger It’s a natural human phenomenon. After a period of intense activity, it’s perfectly understandable to relax, take a step back and catch...
21 May, 2020 Impact of COVID-19 on the R&W insurance market By Paul Tiger Paul Humphreys Tomas Rua The impact of COVID-19 on M&A activity in global markets has predictably had knock-on effects on global R&W insurance markets with deal...
14 May, 2020 Tougher controls for foreign investment – the new normal By Aimen Mir We here at Freshfields are conscious that you are receiving a significant amount of COVID-19 related materials at present, but we wanted...